Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 3/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26324877 | 0.84 | ADRB2 (0.41) | ADRB2ADRB1ADRB3CYP2D6PTGS1 | |
| SCHEMBL15509647 | 0.83 | ADRB2 (0.47) | ADRB2ADRB1ADRB3CYP2D6PTGS1 | |
| SCHEMBL12912652 | 0.80 | KISS1R (0.71) | ADRB2ADRB1ADRB3CYP2D6KISS1R | |
| SCHEMBL12891638 | 0.78 | KISS1R (0.50) | ADRB2ADRB1ADRB3KISS1R | |
| SCHEMBL12891643 | 0.78 | KISS1R (0.50) | ADRB2ADRB1ADRB3KISS1R | |
| SCHEMBL16173875 | 0.77 | ADRB2 (0.40) | ADRB2ADRB1ADRB3CYP2D6PTGS1 | |
| SCHEMBL4373913 | 0.76 | — | — | |
| SCHEMBL4139553 | 0.76 | — | — | |
| SCHEMBL4374793 | 0.76 | — | — | |
| SCHEMBL18647360 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11229709-B2 | Dendrimer drug conjugates for sustained intra-articular delivery | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210017400-A1 | Molecularly Well-defined Antibiofouling and Polyionic Coatings | ACatechol, Inc. (US) | 2021-01-21 | — | — | US | disclosed |
| US-20200155692-A1 | DENDRIMER DRUG CONJUGATES FOR SUSTAINED INTRA-ARTICULAR DELIVERY | UNITED STATES GOVERNMENT | 2020-05-21 | — | — | US | disclosed |
| WO-2019005966-A1 | DENDRIMER DRUG CONJUGATES FOR SUSTAINED INTRA-ARTICULAR DELIVERY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155692-A1 | DENDRIMER DRUG CONJUGATES FOR SUSTAINED INTRA-ARTICULAR DELIVERY | CD44, ITGA6, ITGA2B | ADRB2 2104/4885ADRB1 2090/4885ADRB3 2375/4885 |
| US-11229709-B2 | Dendrimer drug conjugates for sustained intra-articular delivery | CD44, ITGA6, ITGA2B | ADRB2 2104/4885ADRB1 2090/4885ADRB3 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.